In the recent PAR008 release PAR management claimed that there was not just cartilage preservation but growth. This is unheard of in any OA medication study.
So why is there a lack of scientific or media interest?
Why is there a lack of exuberance in the AGM on this point?
Why is there an increase in short interest?
Why would non-executive directors leave?
Why the lack of peer review that has always been promised, for a number of years?
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
42.0¢ |
Change
0.010(2.44%) |
Mkt cap ! $166.9M | |||
| Open | High | Low | Value | Volume |
| 40.0¢ | 42.0¢ | 40.0¢ | $168.2K | 411.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3500 | 41.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 42.0¢ | 50665 | 2 |
View Market Depth
| Last trade - 16.11pm 18/07/2025 (20 minute delay) ? |
| PAR (ASX) Chart |